In this trial of patients with esophageal varices, patients were randomized to carvedilol 12.5 qday or variceal banding (q2 weeks until eradication). Carvedilol patients had significantly fewer variceal bleeding episodes compared to banding (10% vs 23%), with no difference in mortality or bleeding-related mortality. Carvediolol is reasonable for primary prevention of variceal bleeding (abstract).
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.